64CuCl2 PET/CT在前列腺癌复发中的应用
前瞻性评估50例生化复发前列腺癌患者,所有患者均行64CuCl2 PET/CT、18F-胆碱PET/CT和多参数MRI。64CuCl2 PET/CT总检出率为82%,18F-胆碱PET/CT为56%,多参数MRI为74%,64CuCl2 PET/CT与18F-胆碱PET/CT检出率差异有统计学意义(P<0.001)。在PSA小于1 ng/mL的患者中,64CuCl2 PET/CT检出率高于18F-胆碱PET/CT。
要点
- 64CuCl2 PET/CT在生化复发前列腺癌患者中总检出率为82%。
- 64CuCl2 PET/CT检出率82%高于18F-胆碱PET/CT的56%,差异有统计学意义(P<0.001)。
- PSA小于1 ng/mL的患者中,64CuCl2 PET/CT检出率高于18F-胆碱PET/CT。
核心结论
- 64CuCl2的生物分布比18F-胆碱更适合探查骨盆和前列腺床。
- 64CuCl2的有效剂量与其他成熟PET示踪剂相当。
- 在生化复发且PSA水平低的患者中,64CuCl2 PET/CT检出率显著高于18F-胆碱PET/CT。
研究设计与样本
- 前瞻性评估50例手术后或外照射放疗后生化复发的前列腺癌患者。
- 所有患者均在15天内完成64CuCl2 PET/CT、18F-胆碱PET/CT和多参数MRI检查。
- 由经验丰富的阅片者判读图像并计算各影像模态的检出率。
- 采用组织病理学(如有)、临床或实验室反应及多学科随访确认病变部位。
- 同时评估64CuCl2的生物分布、病灶动力学和辐射剂量学。
主要发现
- 给予64CuCl2 200 MBq时,有效剂量为5.7 mSv。
- 与18F-胆碱不同,64CuCl2不经泌尿系统排泄或蓄积,允许全面探查骨盆。
- 前列腺癌复发部位的最大64CuCl2摄取在注射示踪剂后1小时观察到。
- 64CuCl2 PET/CT在50例患者中41例阳性,总检出率为82%。
- 18F-胆碱PET/CT和多参数MRI的检出率分别为56%和74%。
关键数值与推荐
- 64CuCl2 PET/CT总检出率为82%(41/50)。
- 18F-胆碱PET/CT检出率为56%。
- 多参数MRI检出率为74%。
- 64CuCl2 PET/CT与18F-胆碱PET/CT检出率差异有统计学意义(P<0.001)。
- 给予64CuCl2 200 MBq时有效剂量为5.7 mSv。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our objective was to evaluate the biodistribution, kinetics, and radiation dosimetry of 64CuCl2 in humans and to assess the ability of 64CuCl2 PET/CT to detect prostate cancer (PCa) recurrence in patients with biochemical relapse. Methods: We prospectively evaluated 50 PCa patients with biochemical relapse after surgery or external-beam radiation therapy. All patients underwent 64CuCl2 PET/CT, 18F-choline PET/CT, and multiparametric MRI within 15 d of each other. Experienced readers interpreted the images, and the detection rate (DR) of each imaging modality was calculated. Histopathology, when available; clinical or laboratory response; and multidisciplinary follow-up were used to confirm the site of disease. In parallel, biodistribution, kinetics of the lesions, and radiation dosimetry of 64CuCl2 were evaluated. Results: From a dosimetric point of view, an administered dose of 200 MBq for 64CuCl2 translated into a 5.7-mSv effective dose. Unlike 18F-choline, 64CuCl2 was not excreted or accumulated in the urinary tract, thus allowing thorough pelvic exploration. The maximum 64CuCl2 uptake at the sites of PCa relapse was observed 1 h after tracer injection. In our cohort, 64CuCl2 PET/CT proved positive in 41 of 50 patients, with an overall DR of 82%. The DRs of 18F-choline PET/CT and multiparametric MRI were 56% and 74%, respectively. The difference between the DRs of 64CuCl2 PET/CT and 18F-choline PET/CT was statistically significant (P < 0.001). Interestingly, on considering prostate-specific antigen (PSA) value, 64CuCl2 PET/CT had a higher DR than 18F-choline PET/CT in patients with a PSA of less than 1 ng/mL. Conclusion: The biodistribution of 64CuCl2 is more suitable than that of 18F-choline for exploring the pelvis and prostatic bed. The 64CuCl2 effective dose is like those of other established PET tracers. In patients with biochemical relapse and a low PSA level, 64CuCl2 PET/CT shows a significantly higher DR than 18F-choline PET/CT.
引用
- Piccardo A, Paparo F, Puntoni M, et al. 64CuCl2 PET/CT in Prostate Cancer Relapse. J Nucl Med. 2017. PMID: 28887398. doi:10.2967/jnumed.117.195628
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。